Drug delivery systems

Details Drug delivery systems Drug delivery systems

1996-09-09

1998-02-10

Kumar, Shailendra

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

514562, 514563, 558 44, 558 47, 558 52, 558 53, 558 54, 564138, A61K 31255, C07C30906, C07C23102

Patent

active

057169900

ABSTRACT:
Nitrogen mustard pro-drugs of the formula ##STR1## are disclosed where R is the residue of an .alpha.-amino acid RNH.sub.2 and M is a disubstituted amino "mustard" group, useful in antibody directed enzyme pro-drug therapy in the treatment of cancer.

REFERENCES:
patent: 2631164 (1953-05-01), Weisblat et al.
patent: 4185111 (1980-01-01), Ducep et al.
patent: 4564675 (1986-01-01), Kurabayashi et al.
patent: 4675187 (1987-06-01), Konishi et al.
patent: 4762707 (1988-08-01), Jansen et al.
patent: 4975278 (1990-12-01), Senter et al.
A. R. Ahmed et al., Ccyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses, J. Am. Acad. Dermatol., Dec. 1984, pp. 1115-1126.
K. D. Bagshawe, Third Gordon Hamilton-Fairley Memorial Lecture, "Tumour markers-Where do we go from here?", Br. J. Cancer, 48, pp. 167-175 (1983).
I. Hellstrom et al., "Monoclonal Mouse Antibodies Raised Against Human Lung Carcinoma", Cancer Research, 46, pp. 3917-3923 (Aug. 1986).
G. W. Philpott et al., "Affinity Cytotoxicity of Tumor Cells With Antibody-Glucose Oxidase Conjugates, Peroxidase, and Arspehnamine", Cancer Research, pp. 2159-2164 (Sep. 1974).
I. Hellstrom et al., "Monoclonal Antibodies to Two Determinants of Melanoma-Antigen p97 Act Synergistically in Complement-Dependent Cytotoxicity", The Journal of Immunology, 127(1). pp. 157-160 (Jul. 1981).
V. J. Stella et al., "Prodrugs: A Chemical Approach to Targeted Drug Delivery", Directed Drug Delivery, pp. 247-267 (1985).
T. Nishiyama et al., "Antineoplastic Effects in Rats of 5-Fluorocytosine in Combination with Cytosine Deaminase Capsules", Cancer Research, 45, pp. 1753-1761 (Apr., 1985).
D. E. V. Wilman, "Prodrugs in Cancer Chemotherapy", Biochemical Society Transactions, 14, pp. 375-382, (615th Meeting, Belfast 1986).
P. J. O'Dwyer et al., The New England Journal of Medicine, 312, pp. 692-700 (Mar. 14, 1985).
A. P. Albino et al., "Heterogeneity in Surface Antigen and Glycoprotein Expression of Cell Lines Derived from Different Melanoma Metastases of the Same Patient", J. Exp. Med., 154, pp. 1764-1778 (Dec. 1981).
R. Amon et al., "In Vitro and In Vivo Efficacy of Conjugates of Daunomycin with Anti-Tumor Antibodies", Immunological Rev., 62, pp. 5-27 (1982).
K. D. Bagshawe, "Antibody Directed Enzymes Revive Anti-Cancer Prodrugs Concept", Br. J. Cancer, 56, pp. 531-532 (Nov. 1987).
K. D. Bagshawe, "A Novel Approach to Prodrug Activation Using a Monoclonal Antibody Conjugated to Carboxypeptidase G2", from the Third International Conference on Monoclonal Antibody Immunoconjugates for Cancer, Abstract #43, p. 70 (San Diego, Feb. 4-6, 1988).
R. W. Baldwin et al., "Design and Therapeutic Evaluation of Monoclonal Antibody 791T/36-Methotrexate Conjugates", Monoclonal Antibodies and Cancer Therapy, pp. 215-231 (1985).
R. W. Baldwin et al., Monoclonal Antibodies in Cancer Treatment, Lancet, pp. 503-605 (Mar. 15, 1986).
R. W. Baldwin et al., "Monoclonal Antibody Drug Conjugates for Cancer Therapy" Monoclonal Antibodies in Cancer: Advances in Diagnosis and Treatment, pp. 215-257 (1986).
J. P. Brown et al., "Structural Characterization of Human Melanoma-Associated Antigen p97 with Monoclonal Antibodies", J. Immunology, 127(2) pp. 539-546 (Aug., 1981).
E. A. Clark et al., "Role of the Bp35 Cell Surface Polypeptide in Human B-Cell Activation", Proc.Natl. Acad.Sci., 82, pp. 1766-1770 (Mar. 1985).
S. T. Crook et al., (eds) Anthracyclines: Current Status and New Developments, Academic Press, cover pages and table of contents, (New York, 1980).
R. A. DeWeger et al., "Eradication of Murine Lymphoma and Melanoma Cells by Chlorambucil-Antibody Complexes", Immunological Rev., 62, pp. 29-45 (1982).
M. J. Embelton et al., "Antibody Targeting of Anti-Cancer Agents", Monoclonal Antibodies for Cancer Detection and Therapy, pp. 321-322 (1985).
M. J. Embelton et al., "Targeting of Anti-Cancer Therapeutic Agents by Monoclonal Antibodies", Biochemical Society Transactions, 14, pp. 393-395 (615th Meeting, Belfast 1986).
N. Endo et al., "In Vitro Cycotoxicity of a Human Serum Albumin-Medicated Conjugate of Methotrexate with Anti-MM46 Monoclonal Antibody", Cancer Research, 47, pp.1076-1080 (Feb. 15, 1987).
I. Hellstrom et al., "Antitumor Effects of L6, an IgG2a Antibody that Reacts with Most Human Carcinomas", Pro.Natl.Acad.Sci.U.S.A., 83, pp. 7059-7063 (Sep. 1986).
I. Hellstrom et al., "Antibodies for Drug Delivery", Controlled Drug Delivery, (2nd Ed.) pp. 638-642 (1987).
P. L. Ipata et al., "Baker's Yeast Cytosine Deaminase. Some Enzymic Properties and Allosteric Inhibition by Nucleosides and Nucleotides", Biochemistry, 10(23) pp. 4270-4276 (1971).
T. Katsuragi et al., "Affinity Chromatography of Cytosine Deaminase from Excherichia coli with Immobilized Pyrimidine Compounds", Agric. Biol. Chem., 50(7), pp. 1713-1719 (1986).
J.M. Lambert et al., "Purified Immunotoxins That Are Reactive with Human Lymphoid Cells", J. Biol. Chemistry, 260(22), pp. 12035-12041 (1985).
R. W. Baldwin et al. (eds), pp. 53-64, Academic Press (1985).
R. B. McComb et al. (eds), Alkaline Phosphatase, Plenum Press, Chapters 4, 5, 6 and 11 (New York 1979).
R. G. Melton et al., "In Vivo Localization of Carboxypeptidase G2-Antibody Conjugates in Human Colon Carcinoma Xenografts", from the Third International Conference on Monoclonal Antibody Immunoconjugates for Cancer, Abstract #83, p. 110 (San Diego, Feb. 4-6, 1988).
S. Monfardini et al. (eds), Manual of Cancer Chemotherapy, Third Ed., UICC Technical Support Series, 56, Table of Contents, pp. 1-230 (Geneva 1981).
F. L. Moolten et al., "Antibodies Conjugated to Potent Cytotoxins as Specific Antitumor Agents", Immunological Rev., pp. 47-73 (1982).
C. W. Parker et al., "Enzymatic Activation and Trapping of Luminol-Substituted Peptides and Proteins. A Possible Means of Amplifying the Cytotoxicity of Anti-Tumor Antibodies", pro. Nat.Acad.Sci. USA, 72(1), pp. 338-342 (1975).
G. W. Philpott et al., "Selective Iodination and Cytotoxicity of Tumor Cells with an Antibody-Enzyme Conjugate", Surgery, 74(1), pp. 51-58 (1975).
G. W. Philpott et al., "Selective Cytotoxicity of Hapten-Substituted Cells with an Antibody--Enzyme Conjugate", The Journal of Immunology, 111(3), pp. 921-929 (1973).
M. J. Robins et al., "Nucleic Acid Related Compounds. 16. Direct Fluorination of Uracil Nucleotides Using Trifluoromethyl Hypofluorite", Can. J. Chem., 53, pp. 1302-1306 (1975).
G. F. Rowland et al., "Drug Localisation and Growth Inhibition Studies of Vindesine-Monoclonal Anti-CEA Conjugates in a Human Tumour Xenograft", Cancer Immunol Immunother. 21, pp. 183-187 (1986).
F. Searle et al., "Antibody Carboxypeptidase G2 Conjugates as Anti-Tumor Agent", Tumor Biology, 6(4), p. 355 (1985).
F. Searle et al., "Carboxypeptidase G2 Conjugates with Localizing Anti-Tumour Antibodies: Potential Therapeutic Agents", Tumor Biology, 7(4), p. 320 (1986).
F. Searle et al., "The Potential of Carboxypeptidase G2 Antibody Conjugates as Anti-Tumour Agents. I. Preparation of Antihuman Chorionic Gonadotrophin-Carobyxpeptidase G2 and Cytotoxicity Against JAR Choriocarcinoma Cells In Vitro", Br. J. Cancer, 53, pp. 377-384 (1986).
W. T. Shearer et al., "Cytotoxicity with Antibody-Glucose Oxidase Conjugates Specific for a Human Colonic Cancer and Carcinoembryonic Antigen", Int. J. Cancer, 14, pp. 539-547 (1974).
V. J. Stella et al., "Prodrugs Do They Have Advantages in Clinical Practice?", Drugs, 29, pp. 455-473 (1985).
W. A. Thomas, "Prodrugs", Biochemical Society Transactions, 14, pp. 383-387, (615th Meeting, Belfast 1986).
P. E. Thorpe et al., "The Preparation and Cytotoxic Properties of Antibody-Toxin Conjugates", Immunological Rev., 62, pp. 119-158 (1982).
P. E. Thorpe, "Antibody Carriers of Cytotoxic Agents in Cancer Therapy: A Review", Monoclonal Antibodies '84 Biological and Clinical Applications, pp. 475-506 (1985).
E. S. Vitetta et al., "Redesigning Nature's Posions to Create Anti-Tumor Reagents", Science, 238, pp. 1098-1104 (1987).
M. Y. Yeh et al., "Cell Surface Antigens of Human Melanoma Identified by Monoclonal Antibody", Proc.Natl.Acad.Sci (USA, 76(6), pp. 2927-2931 (1979).
M. Y. Yeh et al., "

Affiliated with

Also associated with

Rating

Drug delivery systems does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Drug delivery systems, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug delivery systems will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2077768